摘要
白血病是一类起源于造血干细胞的恶性克隆性疾病,越来越多的研究证明,白血病干细胞(LSC)是白血病复发的根源,其具有与正常造血干细胞类似的无限增殖和自我更新能力,且LSC处于静止期,能逃逸化学药物的治疗作用,从而导致白血病复发和难治。其中,白血病复发及其难治与LSC表面分子标志物及分化抗原表达密切相关。因此,以LSC特异性表面抗原或分子标志物为靶点,寻找和发现治疗白血病的生物靶向药物已成为可能治愈白血病研究的重点。
Leukemia is one of the malignant cloning diseases derived from hematopoietic stem cell.There are more and more researches showing that leukaemia stem cell(LSC)is the origin of the recurrence of leukemia,which has the similarity with the normal haemopoietic stem cell in infinite proliferation and self-renewing.And LSC can get away with the effect of drugs in its resting stage and lead to the recurrent and refractory leukemia.The relapse and refractory of leukemia are closely related to the high expression of differentiation antigens and the surface molecular markers of LSC.Consequently,the biological target drug,which targets specific surface antigens or molecular markers of LSC,has become the new emphasis in the research of leukemia.
出处
《医学综述》
2012年第13期1973-1976,共4页
Medical Recapitulate
基金
教育部高等学校博士点专项基金(20100013110008)
北京中医药大学自主创新课题(2010YYBZZ-XS071)
关键词
白血病干细胞
分子标志物
分化抗原
难治性急性白血病
Leukemia stem cell
Molecular markers
Differentiation antigens
Refractory acute leukemia